Submit a comment

Concentration of Dihydrotestosterone and 3α-Androstanediol in Naturally Occurring and Androgen- Induced Prostatic Hyperplasia in the Dog
Ronald J. Moore, John M. Gazak, James F. Quebbeman, Jean D. Wilson
Ronald J. Moore, John M. Gazak, James F. Quebbeman, Jean D. Wilson
View: Text | PDF
Research Article

Concentration of Dihydrotestosterone and 3α-Androstanediol in Naturally Occurring and Androgen- Induced Prostatic Hyperplasia in the Dog

Abstract

Previous studies have suggested that dihydrotestosterone accumulation in the prostate may be involved in the pathogenesis of prostatic hyperplasia in man and dog. However, the fact that the administration of 10 mg dihydrotestosterone/d to castrated, mongrel dogs (0.5 mg/kg body wt) causes little growth in the prostate, whereas identical doses of 3α- androstanediol regularly induce prostatic hyperplasia (> 14 g weight) has raised the possibility that the dihydrotestosterone accumulation may be the result rather than the cause of the pathology. To investigate the mechanism of this phenomenon, we measured the levels of dihydrotestosterone and 3α-androstanediol in prostates from 75 dogs. In both naturally occurring and 3α-androstanediol-induced prostatic hyperplasia, the levels of dihydrotestosterone were high (>5 ng/g), whereas in immature glands and glands from dihydrotestosterone-treated animals, levels were similar (2.1 and 2.6 ng/g, respectively). 3α-Androstanediol levels were no different in animals treated with dihydrotestosterone or 3α-androstanediol.

Authors

Ronald J. Moore, John M. Gazak, James F. Quebbeman, Jean D. Wilson

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required